Overview
Paige applies AI to digital pathology slides, with an FDA-cleared indication specifically for prostate cancer detection, aimed at pathology labs rather than a general imaging or radiology practice.
It requires a digital pathology system already in place, since it works on scanned slide images rather than film or physical review.
This is a narrower, specialty tool compared to Aidoc or Viz.ai — relevant specifically to labs and practices running pathology review, not general diagnostic imaging.
Pros
- Specific, named FDA clearance for prostate cancer detection
- Purpose-built for digital pathology, not a general imaging add-on
- Reduces missed-finding risk on the indication it covers
Cons
- Requires an existing digital pathology system to use at all
- Narrow indication — not a general-purpose imaging AI tool
- Pricing quoted per lab, not accessible without a sales conversation
Pricing breakdown
- Pricing model
- Custom quote, per lab
- Regulatory note
- FDA-cleared specifically for prostate cancer detection in pathology
- What's included
- AI-assisted slide review integrated with digital pathology systems
Our take
Paige only makes sense if you are running digital pathology and prostate cancer detection is relevant to your case volume. Outside that specific fit, it is not a general diagnostic imaging tool.
Standout feature
FDA-cleared AI for prostate cancer detection in pathology
Visit PaigeThis link may be an affiliate or referral link. It never changes whether a tool is listed or how it is evaluated.
Spot something off?
Pricing and integrations change. Let us know if anything here is outdated.
Suggest a correction